{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:33:37Z","timestamp":1767861217764,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,11,18]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Rifampicin has been widely used due to its broad antibacterial spectrum. Acute haemolysis is a rarely encountered complication of rifampicin. A 58-year-old woman was admitted to our department because of high-grade fever with rigors, accompanied by abdominal and lumbar pain and laboratory evidence of acute haemolysis. She had been treated for brucellosis initially with doxycycline and streptomycin. Due to subsequent appearance of myositis, ciprofloxacin and rifampicin were added for treatment of localised brucellosis. After intravenous administration of rifampicin, the patient deteriorated significantly. After exclusion of other causes of haemolysis, autoimmune haemolytic anaemia related to rifampicin was established by strongly positive direct Coombs test. Drug withdrawal in conjunction with intravenous immune globulin and prednisolone resulted in resolution of haemolysis and no relapse in the ensuing 1-year period. Our case highlights the importance of recognising commonly administrative drugs as cause of haemolytic anaemia, that can often be life threatening.<\/jats:p>","DOI":"10.1136\/bcr-2018-227356","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e227356","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Rifampicin: not always an innocent drug"],"prefix":"10.1136","volume":"11","author":[{"given":"Dafni","family":"Sveroni","sequence":"first","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aggelos","family":"Stefos","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini I","family":"Rigopoulou","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece"},{"name":"Institute of Internal Medicine and Hepatology, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-8464","authenticated-orcid":false,"given":"Georgios N","family":"Dalekos","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece"},{"name":"Institute of Internal Medicine and Hepatology, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,9]]},"reference":[{"key":"2025082707273299000_11.1.e227356.1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.678832"},{"key":"2025082707273299000_11.1.e227356.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.004"},{"key":"2025082707273299000_11.1.e227356.3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21307\/immunohematology-2019-328","article-title":"An update on drug-induced immune hemolytic anemia","volume":"23","author":"Garratty","year":"2007","journal-title":"Immunohematology"},{"key":"2025082707273299000_11.1.e227356.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.0958-7578.2004.00481.x"},{"key":"2025082707273299000_11.1.e227356.5","unstructured":"Brucellosis. In Hellenic Society for Infectious Diseases and the Hellenic Center for Disease Control and Prevention guidelines for the diagnosis and management of infectious diseases. Hellenic Society for Infectious Diseases. 2nd edn. Athens: Focus on Health Ltd, 2015:361\u20136."},{"key":"2025082707273299000_11.1.e227356.6","first-page":"118","article-title":"Rates and risk factors for discontinuation of rifampicin","volume":"4","author":"Cook","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025082707273299000_11.1.e227356.7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.2.115"},{"key":"2025082707273299000_11.1.e227356.8","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.11-0598"},{"key":"2025082707273299000_11.1.e227356.9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/0049475517724689","article-title":"Rifampicin-induced immune allergic reaction","volume":"48","author":"Sadanshiv","year":"2018","journal-title":"Trop Doct"},{"key":"2025082707273299000_11.1.e227356.10","first-page":"246","article-title":"Rifampicin-induced immune hemolytic anemia: therapeutic relevance of plasma exchange","volume":"59","author":"Govoni","year":"1990","journal-title":"Vox Sang"},{"key":"2025082707273299000_11.1.e227356.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5861.282"},{"key":"2025082707273299000_11.1.e227356.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25285169202.x"},{"key":"2025082707273299000_11.1.e227356.13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1024\/1661-8157.98.4.179","article-title":"Renal failure and hemolytic anemia. Rifampicin associated interstitial nephropathy with immune hemolytic anemia","volume":"98","author":"Bodmer","year":"2009","journal-title":"Praxis"},{"key":"2025082707273299000_11.1.e227356.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03416.x"},{"key":"2025082707273299000_11.1.e227356.15","first-page":"554","article-title":"Interstitial nephritis, autoimmune hemolytic anemia, and rifampicin","volume":"18","author":"P\u00eda Iglesias","year":"2001","journal-title":"An Med Interna"},{"key":"2025082707273299000_11.1.e227356.16","first-page":"182","article-title":"Immune hemolytic anemia and acute kidney failure due to rifampicin","volume":"85","author":"Guzzini","year":"1994","journal-title":"Recenti Prog Med"},{"key":"2025082707273299000_11.1.e227356.17","first-page":"391","article-title":"Immune hemolytic anemia caused by rifampicin","volume":"87","author":"Trujillo Conde","year":"1986","journal-title":"Med Clin"},{"key":"2025082707273299000_11.1.e227356.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5770.343"},{"key":"2025082707273299000_11.1.e227356.19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/ajkd.1998.v31.pm9428460","article-title":"Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features","volume":"31","author":"De Vriese","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025082707273299000_11.1.e227356.20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21709"},{"key":"2025082707273299000_11.1.e227356.21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2169\/internalmedicine.53.0936","article-title":"Two cases of autoimmune hemolytic anemia secondary to brucellosis: a review of hemolytic disorders in patients with brucellosis","volume":"53","author":"Eskazan","year":"2014","journal-title":"Intern Med"},{"key":"2025082707273299000_11.1.e227356.22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21307\/immunohematology-2019-102","article-title":"How we investigate drug-induced immune hemolytic anemia","volume":"30","author":"Leger","year":"2014","journal-title":"Immunohematology"},{"key":"2025082707273299000_11.1.e227356.23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1537-2995.2004.03360.x","article-title":"Persistence of cefotetan on red blood cells","volume":"44","author":"Davenport","year":"2004","journal-title":"Transfusion"},{"key":"2025082707273299000_11.1.e227356.24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"British Society for Haematology Guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"2025082707273299000_11.1.e227356.25","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.ejim.2011.07.010","article-title":"Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions","volume":"22","author":"Argyraki","year":"2011","journal-title":"Eur J Intern Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-227356","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:27:38Z","timestamp":1756304858000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,9]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-227356"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227356","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}